About Xiamen Amoytop Biotech Company

The company takes immune-related cytokine drugs as its main research direction, and is committed to becoming a leader in cytokine drug-based systemic immunity solutions to provide better solutions for the treatment of major diseases such as viral hepatitis and malignant tumors. The company is an innovative biomedical enterprise mainly engaged in R&D, production and sales of recombinant proteins and long-term modified drugs. The company's products are Pegbin, Pegin, Terli, Terzine, and Telcon. Corporate honors: 2023 Top 100 Pharmaceutical Innovation Enterprises, China's Top 100 Listed Companies Growing, Fujian Province's Top 100 Innovative Private Enterprises, China's Liver Disease Diagnosis and Treatment Technology Silver Diamond Award, National Innovative Enterprise, Fujian Strategic Emerging Industry Key Enterprise, National Torch Program Key High-tech Enterprise, Postdoctoral Research Workstation, the first prize of the 2023 Xiamen Science and Technology Progress Award, “2023 Top 20 Advances in Chinese Pharmaceutical Biotechnology”, “2023 Top 20 Chinese Biomedical (Including Blood Products, Vaccines, Insulin, etc.) Companies”.